Trapidil for use in the therapy of syndrome that may be influenced by immunomodulators

• US 6,015,578 A
• Filed: 10/09/1997
• Issued: 01/18/2000
• Est. Priority Date: 04/13/1995
• Status: Expired due to Fees

• Current Assignee: UCB SA
• Original Assignee: Rodleben Pharma GmbH
• Inventors: Walch, Hatto
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Benston, Jr., William Edward
• Application Number:
  US08/945,216
• Time in Patent Office: 831 Days
• Field of Search: 424/464, 424/181.1, 424/465
• US Class Current: 424/464
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 33/02 Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Trapidil is used in the therapy of syndromes that may be influenced by immunomodulators. Trapidil is used for the preparation of a drug for the therapy or prophylaxis of diseases associated with TNF-induced pathological disorders.

Claims

1. A method for the therapy of diseases which respond to substances with immunomodulatory activity comprising administration to a patient a drug comprising Trapidil as an immunomodulating active ingredient.

2. A method for treating diseases which are related to TNF-related pathological disturbances comprising administration of Trapidil to retard TNF-α

activity along with medicine used to treat the disease.

3. The method according to claim 2 wherein the disease is associated with leukocyte-derived cytokins of the tumour necrosis factor (TNF).

4. The method of claim 2 wherein the Trapidil dosage units in drug form are between 10 mg and 500 mg.

5. The method of claim 2 wherein a compound of the interferon is administered additionally by one of, in combination with the Trapidil or by separate administration.

6. The method of claim 2 wherein an active ingredient promoting TNF production is administered in addition to the Trapidil by one of jointly or separately side by side.

7. The method of claim 2 wherein, in addition to the Trapidil, a glucocorticoid is administered in combination therewith by one of jointly or separately.

8. The method for treating diseases according to claim 2 wherein the diseases are associated with leukocyte-derived cytokins of the tumour necrosis factor (TNF).

9. The method according to claim 8 wherein the Trapidil dosage units in drug form are between 10 mg and 500 mg.

10. The method according to claim 8 wherein a compound of the interferon is applied additionally by one of, in combination with the Trapidil jointly or by separate administration.

11. The method according to claim 8 wherein an active ingredient promoting TNF production is administered in addition to the Trapidil by one of jointly or separately side by side.

12. The method according to claim 8 wherein, in addition to the Trapidil, a glucocorticoid is administered in combination therewith by one of jointly or by separate administration.

13. The method according to claim 3 wherein the Trapidil dosage units in drug form are between 10 mg and 500 mg.

14. The method according to claim 3 wherein a compound of the interferon is administered additionally by one of, in combination with the Trapidil jointly or by separate administration.

15. The method according to claim 3 wherein an active ingredient promoting TNF production is administered in addition to the Trapidil by one of jointly or separately side by side.

16. The method according to claim 3 wherein, in addition to the Trapidil, a glucocorticoid is administered in combination therewith by one of jointly or by separate administration.

17. The method according to claim 4 wherein a compound of the interferon is administered additionally by one of, in combination with the Trapidil jointly or by separate administration.

18. The method according to claim 4 wherein an active ingredient promoting TNF production is administered in addition to the Trapidil by one of jointly or separately side by side.

19. The method according to claim 4 wherein, in addition to the Trapidil, a glucocorticoid is administered in combination therewith by one of jointly or by separate administration.